Back to results
US 12,577,309 B2Granted
Anti-CSF1R molecules and use thereof
AssigneeDragonboat Biopharmaceutical (Shanghai) Co., Ltd.
InventorsFangyong Du, Peter Peizhi Luo, Yan Li, Guizhong Liu, Xiaohong She, Zhengxi Dai
Life of this patent
Estimating the term…
Abstract
The disclosure relates to antibodies against human CSF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Claims10
An isolated monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human colony stimulating factor 1 receptor (CSF-1R) and comprises
- (1) a heavy chain variable domain (VH) comprising a complementary determining region (CDR) 1 as set forth in SEQ ID NO:
- 1, a CDR2 as set forth in SEQ ID NO:
- 11 and a CDR3 as set forth in SEQ ID NO:
- 21, and a light chain variable domain (VL) comprising a CDR1 as set forth in SEQ ID NO:
- 31, a CDR2 as set forth in SEQ ID NO:
- 41 and a CDR3 as set forth in SEQ ID NO:
- 51;
- (2) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 2, a CDR2 as set forth in SEQ ID NO:
- 12 and a CDR3 as set forth in SEQ ID NO:
- 22, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 32, a CDR2 as set forth in SEQ ID NO:
- 42 and a CDR3 as set forth in SEQ ID NO:
- 52;
- (3) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 3, a CDR2 as set forth in SEQ ID NO:
- 13 and a CDR3 as set forth in SEQ ID NO:
- 23, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 33, a CDR2 as set forth in SEQ ID NO:
- 43 and a CDR3 as set forth in SEQ ID NO:
- 53;
- (4) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 4, a CDR2 as set forth in SEQ ID NO:
- 14 and a CDR3 as set forth in SEQ ID NO:
- 24, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 34, a CDR2 as set forth in SEQ ID NO:
- 44 and a CDR3 as set forth in SEQ ID NO:
- 54;
- (5) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 5, a CDR2 as set forth in SEQ ID NO:
- 15 and a CDR3 as set forth in SEQ ID NO:
- 25, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 35, a CDR2 as set forth in SEQ ID NO:
- 45 and a CDR3 as set forth in SEQ ID NO:
- 55;
- (6) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 6, a CDR2 as set forth in SEQ ID NO:
- 16 and a CDR3 as set forth in SEQ ID NO:
- 26, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 36, a CDR2 as set forth in SEQ ID NO:
- 46 and a CDR3 as set forth in SEQ ID NO:
- 56;
- (7) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 7, a CDR2 as set forth in SEQ ID NO:
- 17 and a CDR3 as set forth in SEQ ID NO:
- 27, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 37, a CDR2 as set forth in SEQ ID NO:
- 47 and a CDR3 as set forth in SEQ ID NO:
- 57;
- (8) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 8, a CDR2 as set forth in SEQ ID NO:
- 18 and a CDR3 as set forth in SEQ ID NO:
- 28, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 38, a CDR2 as set forth in SEQ ID NO:
- 48 and a CDR3 as set forth in SEQ ID NO:
- 58;
- (9) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 9, a CDR2 as set forth in SEQ ID NO:
- 19 and a CDR3 as set forth in SEQ ID NO:
- 29, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 39, a CDR2 as set forth in SEQ ID NO:
- 49 and a CDR3 as set forth in SEQ ID NO:
- 59;
- or
- (10) a VH comprising a CDR1 as set forth in SEQ ID NO:
- 10, a CDR2 as set forth in SEQ ID NO:
- 20 and a CDR3 as set forth in SEQ ID NO:
- 30, and a VL comprising a CDR1 as set forth in SEQ ID NO:
- 40, a CDR2 as set forth in SEQ ID NO:
- 50 and a CDR3 as set forth in SEQ ID NO:
- 60.
68 more elements
Dependencies are inferred from the claim text.